Gastric Cancer – Medxy AI

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Clinical Updates Wellness & Lifestyle

Electroacupuncture Significantly Shortens Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: Insights from a Multicenter Randomized Trial

By MedXY 08/26/2025

This multicenter randomized trial demonstrates that electroacupuncture reduces postoperative ileus duration and accelerates gastrointestinal recovery after laparoscopic gastrectomy for gastric cancer, outperforming sham and standard care.

Clinical Updates Wellness & Lifestyle

Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations

By MedXY 08/05/2025

A comprehensive meta-analysis confirms that Helicobacter pylori eradication reduces gastric cancer risk and related deaths, especially benefiting high-risk groups, supporting widespread screening and treatment.

Medical News Wellness & Lifestyle

Is Your Practice Missing the Next Gastric Cancer Surge?

By MedXY 08/03/2025

A new study predicts 11.8 million gastric cancer cases linked to Helicobacter pylori infection among children born 2008-2017, urging stronger global prevention and vaccine development.

Clinical Updates Wellness & Lifestyle

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

Clinical Updates Wellness & Lifestyle

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.